ADGRE3 Gene Expression Testing for Respiratory Virus Mortality Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the mortality risk of patients infected with respiratory viruses like SARS-COV-2 are not suitable for routine clinical practice due to high implementation time, lack of standardization, low reproducibility, and substantial cost, necessitating the development of alternative approaches for early identification of mortality risk.
Innovation Solution
An in vitro method involving the measurement of ADGRE3 gene expression levels in a biological sample, optionally combined with additional genes, and comparison to predetermined reference values to determine the risk of death, utilizing RT-PCR for quantification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If mixed flow cytometry approaches and multiplex analysis are used to characterize immune profile, then comprehensive immune characterization is achieved, but implementation time increases and reproducibility decreases
Solution Approach 1:
The patent extracts the essential predictive information from complex immune profiles by identifying a single key biomarker (ADGRE3 gene expression) that captures the most critical prognostic signal. This extraction approach maintains measurement precision for mortality risk assessment while eliminating the variability and complexity of comprehensive immune profiling, thereby improving reproducibility across different laboratories and cohorts.
2Measurement precision
If comprehensive immune profiling methods are used, then detailed immune characterization is obtained, but cost increases substantially
Solution Approach 1:
The patent extracts only the essential prognostic information needed for clinical decision-making by focusing on ADGRE3 gene expression alone. This single-biomarker approach provides sufficient measurement precision for mortality risk stratification while dramatically reducing the substantial costs associated with comprehensive multiplex analysis and flow cytometry panels.
3Measurement precision
If multiple biomarkers are measured for mortality risk prediction, then prediction accuracy may improve, but device complexity and ease of operation deteriorate
Solution Approach 1:
The patent extracts the single most predictive biomarker (ADGRE3) from among multiple potential candidates, thereby maintaining high mortality risk prediction accuracy while dramatically simplifying the testing procedure. This single-gene measurement approach is readily implementable in routine clinical laboratories using standard RT-PCR platforms, making it accessible for widespread clinical use without requiring complex multi-biomarker assays.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid and effective assessment of increased mortality risk in patients, facilitating personalized treatment and early intervention by measuring easily accessible biomarkers through automated devices.
Implementation Method 1
utilizing RT-PCR for quantification
Data Source
AI summary
The invention relates to an in vitro or ex vivo determination method for determining the risk of death of a patient infected by a respiratory virus, said method comprising the steps of measuring, in a biological sample from said patient, the expression level of the ADGRE3 gene, and of comparing the expression level thus measured or a value derived from this quantity with a predetermined reference value. The method thus makes it possible to conclude that there is an increased risk of death of the patient when an underexpression of the ADGRE3 gene is statistically demonstrated from the biological sample. Advantageously, the measurement of the expression level of ADGRE3 can be supplemented by the measurement of one or more additional genes such as C3AR1, CD177, OAS2, CIITA, IL-10, IL1R2, CD74, TDRD9) and combinations thereof. The invention also relates to kits for measuring the expression of ADGRE3 and optionally of one or more additional genes.